FATE THERAPEUTICS INC Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale
FATE THERAPEUTICS INC (FATE) reported Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale of $0 for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-08.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale · last filed 2026-02-26
- FATE THERAPEUTICS INC other-than-temporary impairment loss, debt securities, available-for-sale for the quarter ending 2023-09-30 was $0.00.
- FATE THERAPEUTICS INC other-than-temporary impairment loss, debt securities, available-for-sale for the quarter ending 2023-06-30 was $0.00.
- FATE THERAPEUTICS INC other-than-temporary impairment loss, debt securities, available-for-sale for the quarter ending 2023-03-31 was $0.00.
- FATE THERAPEUTICS INC other-than-temporary impairment loss, debt securities, available-for-sale for the quarter ending 2022-09-30 was $0.00.
- FATE THERAPEUTICS INC other-than-temporary impairment loss, debt securities, available-for-sale for fiscal 2020 was $0.00.
- FATE THERAPEUTICS INC other-than-temporary impairment loss, debt securities, available-for-sale for fiscal 2019 was $0.00.
- FATE THERAPEUTICS INC other-than-temporary impairment loss, debt securities, available-for-sale for fiscal 2018 was $0.00.
- FATE THERAPEUTICS INC other-than-temporary impairment loss, debt securities, available-for-sale for fiscal 2017 was $0.00.
| Period end | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale 3 month | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale 6 month | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale 9 month | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2023-09-30 | $0.00 10-Q · filed 2023-11-08 | $0.00 derived: sum of 2 quarters · filed 2023-11-08 | $0.00 derived: sum of 3 quarters · filed 2023-11-08 | |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-08 | $0.00 derived: sum of 2 quarters · filed 2023-08-08 | ||
| 2023-03-31 | $0.00 10-Q · filed 2023-05-03 | |||
| 2022-09-30 | $0.00 10-Q · filed 2022-11-03 | $0.00 derived: sum of 2 quarters · filed 2022-11-03 | $0.00 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $0.00 10-Q · filed 2022-08-03 | $0.00 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-03 | |||
| 2021-09-30 | $0.00 10-Q · filed 2021-11-04 | $0.00 derived: sum of 2 quarters · filed 2021-11-04 | $0.00 10-Q · filed 2022-11-03 | $0.00 derived: sum of 4 quarters · filed 2026-02-26 |
| 2021-06-30 | $0.00 10-Q · filed 2021-08-04 | $0.00 10-Q · filed 2022-08-03 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $0.00 derived: sum of 4 quarters · filed 2026-02-26 |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-04 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $0.00 derived: sum of 4 quarters · filed 2026-02-26 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 |
| 2020-09-30 | $0.00 10-Q · filed 2021-11-04 | $0.00 derived: sum of 2 quarters · filed 2021-11-04 | $0.00 10-Q · filed 2021-11-04 | $0.00 derived: sum of 4 quarters · filed 2026-02-26 |
| 2020-06-30 | $0.00 10-Q · filed 2021-08-04 | $0.00 10-Q · filed 2021-08-04 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $0.00 derived: sum of 4 quarters · filed 2026-02-26 |
| 2020-03-31 | $0.00 10-Q · filed 2021-05-05 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $0.00 derived: sum of 4 quarters · filed 2026-02-26 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 |
| 2019-09-30 | $0.00 10-Q · filed 2020-11-05 | $0.00 derived: sum of 2 quarters · filed 2020-11-05 | $0.00 10-Q · filed 2020-11-05 | $0.00 derived: sum of 4 quarters · filed 2026-02-26 |
| 2019-06-30 | $0.00 10-Q · filed 2020-08-05 | $0.00 10-Q · filed 2020-08-05 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $0.00 derived: sum of 4 quarters · filed 2026-02-26 |
| 2019-03-31 | $0.00 10-Q · filed 2020-05-11 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $0.00 derived: sum of 4 quarters · filed 2026-02-26 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 |
| 2018-09-30 | $0.00 10-Q · filed 2019-11-05 | $0.00 derived: sum of 2 quarters · filed 2019-11-05 | $0.00 10-Q · filed 2019-11-05 | $0.00 derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $0.00 10-Q · filed 2018-08-06 | $0.00 10-Q · filed 2018-08-06 | $0.00 derived: sum of 3 quarters · filed 2020-03-02 | $0.00 derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | $0.00 10-Q · filed 2019-05-07 | $0.00 derived: sum of 2 quarters · filed 2020-03-02 | $0.00 derived: sum of 3 quarters · filed 2020-03-02 | $0.00 derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $0.00 derived: sum of 2 quarters · filed 2020-03-02 | $0.00 derived: sum of 3 quarters · filed 2020-03-02 | $0.00 10-K · filed 2020-03-02 |
| 2017-09-30 | $0.00 10-Q · filed 2018-11-01 | $0.00 derived: sum of 2 quarters · filed 2018-11-01 | $0.00 10-Q · filed 2018-11-01 | |
| 2017-06-30 | $0.00 10-Q · filed 2018-08-06 | $0.00 10-Q · filed 2018-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |